T-cell invigoration to tumour burden ratio associated with anti-PD-1 response Journal Article


Authors: Huang, A. C.; Postow, M. A.; Orlowski, R. J.; Mick, R.; Bengsch, B.; Manne, S.; Xu, W.; Harmon, S.; Giles, J. R.; Wenz, B.; Adamow, M.; Kuk, D.; Panageas, K. S.; Carrera, C.; Wong, P.; Quagliarello, F.; Wubbenhorst, B.; D'Andrea, K.; Pauken, K. E.; Herati, R. S.; Staupe, R. P.; Schenkel, J. M.; McGettigan, S.; Kothari, S.; George, S. M.; Vonderheide, R. H.; Amaravadi, R. K.; Karakousis, G. C.; Schuchter, L. M.; Xu, X.; Nathanson, K. L.; Wolchok, J. D.; Gangadhar, T. C.; Wherry, E. J.
Article Title: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Abstract: Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical benefit. Pre-existing T-cell infiltration and/or the presence of PD-L1 in tumours may be used as indicators of clinical response; however, blood-based profiling to understand the mechanisms of PD-1 blockade has not been widely explored. Here we use immune profiling of peripheral blood from patients with stage IV melanoma before and after treatment with the PD-1-targeting antibody pembrolizumab and identify pharmacodynamic changes in circulating exhausted-phenotype CD8 T cells (T ex cells). Most of the patients demonstrated an immunological response to pembrolizumab. Clinical failure in many patients was not solely due to an inability to induce immune reinvigoration, but rather resulted from an imbalance between T-cell reinvigoration and tumour burden. The magnitude of reinvigoration of circulating T ex cells determined in relation to pretreatment tumour burden correlated with clinical response. By focused profiling of a mechanistically relevant circulating T-cell subpopulation calibrated to pretreatment disease burden, we identify a clinically accessible potential on-treatment predictor of response to PD-1 blockade. © 2017 Macmillan Publishers Limited, part of Springer Nature.
Journal Title: Nature
Volume: 545
Issue: 7652
ISSN: 0028-0836
Publisher: Nature Publishing Group  
Date Published: 2017-05-04
Start Page: 60
End Page: 65
Language: English
DOI: 10.1038/nature22079
PROVIDER: scopus
PUBMED: 28397821
PMCID: PMC5554367
DOI/URL:
Notes: Article -- Export Date: 1 June 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Michael Andrew Postow
    363 Postow
  3. Phillip Wong
    81 Wong
  4. Katherine S Panageas
    517 Panageas
  5. Deborah Kuk
    87 Kuk
  6. Matthew J Adamow
    24 Adamow